CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

President Trump's new Executive Order aims to lower prescription drug prices by tying U.S. costs to global rates. Read more ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...